

Understanding PCOS Through The Lens Of *Sthoulya* (Obesity) And *Artava Kshaya*: An Integrated Ayurvedic Approach To Metabolic And Reproductive Dysfunction



Dr. Monika Sharma^{1*}, Dr. Mohit Kushwaha²

^{1*}Assistant professor Department of Prasuti Tantra evum stree roga SRM govt. Ayurvedic college and hospital, Bareilly (drmonikapnsharma@gmail.com)

²Associate Professor, Department of Kayachikitsa, Rohilkhand Ayurvedic Medical College and hospital, Bareilly (drmohtkushwaha@gmail.com)

***Corresponding Author-** Dr. Monika Sharma
(drmonikapnsharma@gmail.com)

Abstract

Polycystic Ovary Syndrome (PCOS) is a heterogeneous metabolic-reproductive disorder characterized by insulin resistance, obesity, hyperandrogenism, and chronic anovulation. This article presents an integrated Ayurvedic interpretation of PCOS through the dual frameworks of *Sthoulya* (obesity/*Medoroga*) and *Artava Kshaya* (diminished menstrual function). The proposed *Kapha-Meda Avarana* model explains how systemic metabolic derangement, originating from *Agnimandya* and *Medo Dhatvagni* dysfunction, leads to *Meda vridhhi* and subsequent obstruction of the *Artavavaha Srotas*. This obstruction impairs *Apana Vata*, resulting in anovulation, oligomenorrhea, and follicular arrest—clinical parallels of PCOS. The article also differentiates *Sthoulya*-linked PCOS from lean phenotypes, highlighting distinct doshic drivers. A comprehensive therapeutic protocol integrating *Shodhana*, *Shamana*, *Tarpana*, and *Uttara Vasti* is presented, demonstrating significant improvements in metabolic parameters, normalization of ovarian morphology, restoration of ovulation, and high conception rates in clinical observations. The findings support Ayurveda's capacity to address both the metabolic root (*Sthoulya*) and the reproductive manifestation (*Artava Kshaya*), offering a causally coherent and effective management approach for PCOS.

Keywords

Polycystic Ovary Syndrome (PCOS), *Sthoulya*, *Medoroga*, *Artava Kshaya*, *Kapha-Meda Avarana*, *Apana Vata*, *Dhatvagni Mandya*, Ayurvedic pathogenesis, Metabolic dysfunction, Anovulation, Uttara Vasti, integrated Ayurvedic management

1. Introduction

1.1. Polycystic Ovary Syndrome (PCOS): A Global Health Challenge and Heterogeneous Disorder

Polycystic Ovary Syndrome (PCOS) stands as the most prevalent endocrinopathy affecting women of reproductive age globally, distinguished by a complex interplay of reproductive, metabolic, and dermatological disturbances. Clinically, it manifests as menstrual irregularities, chronic anovulation, hirsutism, acne, and obesity. The syndrome's pathogenesis is decidedly multifactorial, incorporating heritable factors such as polycystic ovarian morphology (PCOM), hyperandrogenemia, insulin resistance (IR), and insulin secretory defects. Environmental components, including prenatal androgen exposure and poor fetal growth, along with acquired obesity, represent major postnatal etiological determinants.¹

The complexity of PCOS stems from the variety of pathways involved and the lack of a singular common pathological thread, underscoring its heterogeneity. Notably, recent studies indicate that PCOS accounts for approximately 80% of anovulatory infertility cases, yet the precise mechanisms driving PCOS-induced anovulation remain indeterminate.

1.2. Bridging the Metabolic-Reproductive Axis through Integrated Pathophysiology

The connection between energy metabolism, specifically obesity and IR, and reproductive function (anovulation and menstrual irregularity) is fundamental to PCOS pathophysiology. Ayurveda provides a sophisticated framework for understanding this nexus through the concepts of *Sthoulya* (Obesity or *Medoroga*) and *Artava Kshaya* (Diminution or deficiency of menstrual flow/anovulation).

Sthoulya correlates with the systemic metabolic disruption, marked by the excessive accumulation and vitiation of *Medodhatu* (adipose tissue). This metabolic disturbance acts as the primary systemic

driver. Conversely, *Artava Kshaya* represents the resulting localized reproductive pathology, characterized by menstrual irregularities and failure of ovulation. This paper rigorously substantiates the *Kapha-Meda Avarana* model, positing it as the mechanistic link that translates metabolic *Sthoulya* into reproductive *Artava Kshaya* in the predominant, metabolically challenged phenotype of PCOS. The objective is to establish a standardized, evidence-based therapeutic rationale founded on this integrated approach.ⁱⁱ

2. Modern Etiopathogenesis and Diagnostic Phenotypes

2.1. The Central Role of Obesity and Insulin Resistance (IR) in PCOS Pathophysiology

Insulin Resistance and subsequent compensatory hyperinsulinemia are recognized as critical elements in PCOS pathogenesis, exerting adverse effects on multiple organ systems. Hyperinsulinemia exacerbates ovarian and adrenal androgen production, inhibits hepatic synthesis of Sex Hormone-Binding Globulin (SHBG), and thus increases free androgen levels, leading to hyperandrogenism, altered serum lipids, and chronic anovulation. Acquired obesity is identified as a major postnatal factor contributing to the development of IR and the severity of PCOS symptoms.

However, the heterogeneity of the disorder must be acknowledged. While obesity and IR are hallmarks for many patients, certain women presenting with typical PCOS symptoms do not exhibit significant insulin resistance, suggesting that a genetic predisposition specific to PCOS exists and that IR may represent an unmasking or amplifying factor rather than the sole etiology in all cases. This clinical distinction underscores the necessity for targeted treatment strategies that can differentiate between metabolic (*Kapha*-dominant) and non-metabolic

(*Vata-Pitta* dominant) phenotypes, echoing the nuanced classification capability of Ayurveda.ⁱⁱⁱ

2.2. Comparison of International Diagnostic Criteria

The clinical definition of PCOS has evolved significantly, resulting in several diagnostic standards that delineate distinct patient phenotypes. A review of these criteria is essential for mapping modern diagnosis to Ayurvedic concepts.

The National Institutes of Health (NIH) criteria, established in 1990, require the presence of both Oligo-Anovulation (OD) and clinical and/or biochemical Hyperandrogenism (HA). The Rotterdam criteria, established in 2003, broadened this definition, requiring the presence of at least two out of three criteria: OD, HA, and Polycystic Ovarian Morphology (PCOM) (defined as 12 follicles measuring 2-9 mm in diameter, or ovarian volume 10 ml in at least one ovary). This resulted in two new phenotypes (HA+PCOM and OD+PCOM) not covered by NIH, increasing the recognized prevalence of PCOS from approximately 7% to up to 15% of reproductive-age women. The Androgen Excess and PCOS Society (AE-PCOS) criteria, established in 2006, centered the diagnosis on hyperandrogenism in combination with OD and PCOM.

The recognition of these varying phenotypes is critical. The *Sthoulya* (Obesity/IR) model proposed in this paper aligns most strongly with the metabolically severe phenotypes defined by the NIH criteria, and Rotterdam phenotypes A (HA+OD+PCOM) and B (HA+OD). These phenotypes are centrally characterized by hyperandrogenism and ovulatory dysfunction, features that are highly correlated with the presence of IR and acquired obesity, thus establishing a strong link to *Kapha-Meda* pathology.

Table 1: Comparative Framework of Modern Diagnostic Criteria for PCOS Phenotypes

Criteria/Syndrome	Required Features	Common Metabolic Profile	Ayurvedic Correlation (Sthoulya Link)
NIH (1990)	Oligo-Anovulation (OD) + Hyperandrogenism (HA)	High IR, Obesity highly common	Strong <i>Kapha-Meda</i> link (Primary focus)
Rotterdam (2003)	2 out of 3: OD, HA, PCOM	Heterogeneous (IR dependent on HA/Obesity status)	Addresses a broader spectrum of <i>Dhatu Dushti</i>
AE-PCOS (2006)	Hyperandrogenism + (OD and/or PCOM)	Emphasizes androgenic severity, strong IR association	Strong <i>Pitta</i> component (Tapas and heat involvement)

3. Sthoulya (Medoroga): The Root of Metabolic Dysfunction

3.1. Defining Sthoulya and Medodhatu Vriddhi in Classics^{iv}

In Ayurvedic literature, obesity is designated as *Sthoulya* or *Medoroga* and is classified under

Santarpanottha Vikara, diseases arising from over-nourishment or excessive consumption. *Sthoulya* is pathologically defined as an abnormal state marked by the excessive accumulation and vitiation of *Medodhatu* (the fat tissue). Classical principles hold that an elevated Body Mass Index (BMI) directly

correlates with an overabundance of *Medo Dhatu*, which subsequently elevates the systemic risk of metabolic disorders such as hyperlipidemia, hypertension, and diabetes. The classical descriptions of *Sthoulya* are found extensively in texts such as the *Charaka Samhita*, highlighting the systemic degradation caused by excessive fat tissue.^v

3.2. Etiology (*Nidana*) and the Principle of *Kapha* Aggravation

The etiology of *Sthoulya* is rooted in *Nidana Sevana* that aggravates *Kapha Dosh*, leading to the production of qualitatively inferior and quantitatively excessive *Meda Dhatu*. These causative factors include the habitual consumption of *Kaphavardhaka Ahara* foods characterized by sweet, salty, oily, heavy, rich, and dense qualities coupled with lifestyle factors such as *Avyayama* (lack of physical activity) and *Diwaswapa* (daytime sleep).

The pathogenesis is initiated by the dominant *Kapha* qualities heavy, cold, sticky (*Guru, Shita, Picchila*), which are associated with the *Prithvi* and *Apa Mahabhutas*. The intake of these specific qualities directly suppresses the body's metabolic efficiency. This aggregation of heavy qualities establishes the environment for metabolic dysfunction, which manifests primarily at the level of the digestive fire.

3.3. Pathophysiology: *Medo Dhatwagni Mandya* and *Ama* Generation

The core metabolic error in *Sthoulya* involves *Mandagni*, the weakening of digestive fire. This dysfunction occurs sequentially, starting at *Jatharagni* (gastrointestinal digestion) and proceeding to the specific tissue fire, *Medo Dhatwagni*. Due to the suppressive influence of vitiated *Kapha*, food intake is not properly digested, resulting in the production of *Ama* (undigested, toxic material).

At the tissue level, *Medo Dhatwagni Mandya* prevents the optimal transformation (*Dhatu Paka Vaishamy*) of the nourishing portion of *Mamsa Dhatu* into functional *Medo Dhatu*. Instead, the hypofunctioning *Dhatwagni* results in the production of excessive, immature, and vitiated *Meda Dhatu* (*Medo Vridhi*), which further compromises metabolic balance.

This systemic pathology establishes a critical feedback loop leading to chronic morbidity. The increase in pathological *Meda* leads to *Sroto Avarodha* (obstruction of microchannels, including *Medovaha Srotas*). This mechanical obstruction restricts the normal *gati* (movement) of *Vata Dosh*, especially *Samana Vayu*, confining it to the *Koshta* (alimentary tract). The trapped *Vayu*, lacking proper

channels, causes *Agni Sandukshana* (the artificial kindling or exacerbation of *Jatharagni*), which presents clinically as excessive appetite (*Ati Kshudha*). This hyperphagia perpetuates the cycle of overeating and fat accumulation, a dynamic pathology that strongly correlates with the modern understanding of leptin resistance and dysregulated hunger signaling observed in chronic obesity. The treatment approach must therefore aim at *Avarana Vimochana* (removing obstruction) and strengthening *Dhatwagni*.

4. *Artava Kshaya*: The Reproductive Manifestation

4.1. Definition and Significance of *Artava Dhatu* and *Artavavaha Srotas*

Artava is defined in Ayurvedic literature as a crucial reproductive element, encompassing both the menstrual blood and the functional ovum, essential for conception. Charaka and Sushruta classify *Artava* as an *Upadhatu* (sub-tissue) derived from *Rasa Dhatu*, highlighting its fundamental importance in the female reproductive system. The physiological processes governing menstruation and ovulation rely on the integrity of the *Artavavaha Srotas* (channels responsible for reproductive flow and nourishment), which have their roots in the *Garbhashayya* (uterus) and *Artava Vahi Dhamani* (arterial channels). Disruptions in these channels (*Srotodushti*) or the quantity/quality of the *Artava* element (*Artava Kshaya*) represent major pathological states leading to *Vandhyatva* (infertility).^{vi}

4.2. Classical *Artava Kshaya Lakshanas* and Modern Correlation

Artava Kshaya refers to the diminution or deficiency of *Artava*. Acharya Sushruta explained the core symptoms (*Rupa*) of *Artava Kshaya* as *Yathochita Kaala Adarshanam* and *Alpartavam*. ***Yathochita Kaala Adarshanam***: This denotes the absence of menstrual flow at the proper time, encompassing prolonged intermenstrual periods (Oligomenorrhea) or complete absence (Amenorrhea).

- ***Alpartavam***: This signifies scanty menstrual flow, defined as a quantity less than normal (e.g., less than four *Anjali* or 35 ml).

Based on these clinical characteristics, *Artava Kshaya* in the context of PCOS is directly correlated with the modern clinical entities of Oligomenorrhea and Hypomenorrhea, which are hallmark diagnostic features of the syndrome.

4.3. Pathogenesis of *Artava Kshaya*: *Kapha Avarana* and *Vata Vaigunya*

The fundamental pathogenesis of *Artava Kshaya* in *Sthoulya*-linked PCOS is established by

Agnimandhyajanya Kapha Vata Dushti. This pathology involves a dual mechanism: mechanical obstruction and functional vitiation.

1. Mechanical Obstruction (Kapha-Meda Avarana): The pathology begins when the vitiated *Kapha* and excessive *Meda Dhatu* produced from *Mandagni* spread and obstruct the *Artavavaha Srotas*. This obstruction, or *Avarana*, physically impedes the flow of *Artava* (manifesting as *Alpartavam* or Hypomenorrhea) and, crucially, prevents the essential nutritional support (*Rasa Dhatu*) from reaching the ovarian tissue, hindering the physiological maturation and release of the ovum. This blockage is

responsible for the characteristic follicular stagnation or *Beejagranthi Vikar*.

2. Functional Vitiation (Apana Vata Vaigunya): *Vata Dosha*, particularly *Apana Vata*, governs the descent and expulsion functions, playing a primary role in ovulation, menstruation, and fertilization. When the *Artavavaha Srotas* are obstructed by the bulky *Kapha-Meda* complex, *Apana Vata* becomes vitiated (*Vaigunya*). This functional impairment disrupts the rhythmic, timely mechanisms of follicular growth and rupture, directly resulting in anovulation and menstrual irregularity (*Yathochita Kaala Adarshanam*)^{vii}

Table 2: Comparative Analysis of Artava Kshaya and Modern Reproductive Features of PCOS

Artava Feature	Kshaya	Classical Description	Pathological Mechanism	Modern PCOS Equivalent
Yathochita Adarshanam	Kaala	Delayed menarche, prolonged intermenstrual period, or amenorrhea	Apana Vata Vaigunya due to Meda Avarana	Oligomenorrhea/Amenorrhea
Alpartavam		Scanty menstrual flow (e.g., 4Anjali)	Mechanical obstruction of Artavavaha Srotas by Kapha/Meda	Hypomenorrhea/Scanty bleeding
Beejagranthi Vikar		Knot-like structures in the ovarian area	Follicular stagnation/arrest due to local Sroto Avarodha	Polycystic Ovarian Morphology (PCOM)

5. Integrated Ayurvedic Pathogenesis of PCOS: The Meda-Artava Avarana Model

5.1. Synthesizing the Disease Complex

PCOS, viewed holistically, is a multisystem disorder rooted in systemic metabolic failure that subsequently localizes to the reproductive tissue. It is appropriately conceptualized as *Dhatwagni Mandya Janya Beejagranthi Vikar* (a disorder of follicular cystic formation arising from hypo-functioning tissue metabolism). The entire pathogenesis relies on the principle of metabolic precedence: adverse lifestyle and dietary factors first precipitate *Sthoulya* (metabolic dysfunction), which then triggers *Artava Kshaya* (reproductive dysfunction) via the mechanism of *Avarana*.

5.2. The Central Role of Kapha-Meda Avarana

The *Kapha-Meda Avarana* model provides a precise explanation for the concurrent presentation of obesity, IR, and anovulation. The accumulated *Meda Dhatu*, being heavy, sticky, and bulky, acts as the primary obstructing agent. This *Meda* physically clogs the *Srotas* the channels not only of fat metabolism but also the microchannels that feed the *Artava Dhatu*.

This physical obstruction results in three interconnected pathological consequences within the ovaries:

1. Impaired Nourishment: The nourishing *Rasa Dhatu* cannot properly reach the developing ovarian follicles, resulting in suboptimal follicular growth.

2. Impaired Function: The vitiated *Apana Vata* cannot perform its function of rupture and expulsion (*Vata Anulomana* failure).

3. Pathological Stasis: The lack of egress combined with constant, aberrant hormonal signaling leads to follicular arrest and the formation of *Granthi* (cysts).

This systemic pathology, following the six stages of *Kriya Kala* (*Sanchaya*, *Prakopa*, *Prasara*, *Sthanasamsraya*, *Vyakta*, *Bheda*), culminates in the clinical picture of PCOS, where *Sthoulya* provides the material for *Avarana* and *Artava Kshaya* is the resultant reproductive outcome.

Flowchart 1: Integrated Ayurvedic Samprapti of Sthoulya-Linked PCOS (Meda-Artava Avarana)

Nidana Sevana (Kapha Aggravation, Avyayama) Agni Vaishamyā (Dhatwagni Mandya) → Ma Utpatti Meda Dhatu Vriddhi (Sthoulya, IR) → Sroto Avarodha (Avarana of Medovaha & Artavavaha Srotas by Meda) → Vata Vaigunya (Apana Vata vitiation) → Sthana Samsraya (Garbhashayya/Ovaries) → Beejagranthi Vikar + Artava Kshaya (Anovulation, Oligomenorrhea)

5.3. Differential Diagnosis: Sthoulya-linked vs. Lean PCOS Phenotypes

It is imperative to differentiate the *Sthoulya*-linked presentation from the Lean PCOS phenotype, as their primary pathological drivers and subsequent treatments diverge significantly. The *Sthoulya*-linked model, dominant in obese and insulin-resistant patients, is fundamentally driven by **Kapha Vriddhi** (providing the material for

Avarana) and **Vata Dushti** (causing functional irregularity). This is a *Santarpanotha Vikara*. In contrast, the Lean PCOS phenotype, often presenting without significant obesity or IR, may not primarily involve *Meda Avarana*. Instead, it may exhibit features of *Apatarpana Vyadhi* (undernourishment) or *Manodoshaja Vikar* (stress/mental factors). The dominant *Doshas* here are typically **Vata and Pitta**, where stress or hyper-

metabolism might drive hormonal dysfunction (hyperandrogenism) without substantial mechanical obstruction by *Meda*. This pathological distinction mandates different therapeutic strategies: *Lekhana* (reduction) and *Srotoshodhana* for *Sthoulya*-linked PCOS, versus *Brimhana* (nourishment) and *Vata/Pitta* balancing for lean PCOS.

Table 3: Comparative Pathology of PCOS Phenotypes

Feature	<i>Sthoulya</i> -Linked PCOS (Obese/Kapha Dominant)	Lean PCOS (<i>Vata-Pitta</i> Dominant)
Ayurvedic Classification	<i>Santarpanotha Vikar / Dhatwagni Mandya</i>	<i>Apatarpanaja / Manodoshaja Vikar</i>
Primary Dosha / Dhatu	<i>Kapha Vriddhi, Meda Vriddhi</i>	<i>Vata Prakopa, Pitta involvement</i>
Pathological Mechanism	<i>Avarana</i> (Obstruction by <i>Meda</i>) leading to <i>Granthi</i>	<i>Dhatu Kshaya / Functional impairment of Vata</i>
Modern Correlation	Insulin Resistance, Metabolic Syndrome, Hyperandrogenism	Potential Ovarian / Adrenal Hyperandrogenism without severe IR

6. Holistic Therapeutic Strategies (*Chikitsa Siddhanta*)

6.1. General Principles: Phased Approach to *Avarana Vimochana*

The management of *Sthoulya*-linked PCOS is centered on the principle of *Avarana Vimochana*—the removal of obstruction to restore metabolic equilibrium and reproductive function. The Ayurvedic treatment regimen is structured sequentially, targeting the systemic *Meda Dhatu Vriddhi* first, followed by localized *Artava* correction. The standard protocol follows the tripartite Ayurvedic theories of *Shodhana* (Purification), *Shamana* (Palliation), and *Tarpana* (Nourishment/Fortification). This structured approach ensures that the root cause (*Mandagni* and *Avarana*) is addressed before attempting to rectify the resultant *Artava Kshaya*.^{viii}

6.2. Stage-Wise Management Protocol (Evidence-Based Regimen)

Clinical studies evaluating integrated Ayurvedic management for subfertility associated with PCOS have employed a structured, 6-month regimen.

Stage 1: *Shodhana* (Purification and Channel Clearance)

This initial stage (typically Day 1 to Day 14) focuses on basic body purification, *Deepana* (appetizer), *Pachana* (digestive), and initiating *Srotoshodhana* to clear systemic *Ama* and alleviate *Kapha*.

Key formulations utilized for this stage include 30 ml of *Triphala Kwatha*, 2 pills of *Chandraprabha Vati*, and 5g of powder of *Manibhadra Choorna*, administered twice daily. *Triphala* and *Chandraprabha Vati* (containing *Guggulu*) are potent *Medohara* and *Srotoshodhaka* agents,

essential for clearing obstruction and promoting weight reduction.

Stage 2: *Shamana* (Palliation and Follicular Enhancement)

This phase (Day 15 up to the 4th month) aims to regulate the hormonal environment, enhance follicular maturation, and improve systemic immunity (*Ojas*).

The regimen focuses on *Artava Janana* and *Balya* agents: 5g of powder of *Shatavari* (*Asparagus racemosus*), *Shatapushpa* (*Peucedanum graveolens*), and *Guduchi* (*Tinospora cordifolia*), administered twice daily. *Shatavari* is crucial for correcting hormonal influence and regulating *Artava Dhatu*. *Shatapushpa* acts as a follicular maturity substance and anti-spasmodic. Additionally, 20 ml of oil of *Krishna Jeeraka* (*Nigella sativa*) is administered twice daily, prized for its potential cystolytic action in the ovaries.

Stage 3: *Tarpana* (Nourishment and Fortification)

This final phase (4th to 6th month) focuses on *Prajasthapana* (supporting conception) and *Ojo Vardhana*. The goal is to fortify the reproductive tissues and remove residual follicular aberrations. This regimen includes 5g of powder of *Atibala* (*Abutilon indicum*) and *Shatapushpa*, alongside 4 pills (125mg each) of a *Rasayana Kalpa* (containing ingredients like *T. chebula*, *T. belerica*, *E. officinalae*, *T. cordifolia*, etc.) twice daily. *Atibala* corrects hormonal disturbances and provides *Balya* (strength) to facilitate conception and avoid miscarriage.

6.3. Specialized Local Management: Efficacy of Uttara Vasti

Localized therapeutic procedures are critical for directly addressing the reproductive pathology (*Artava Kshaya* and *Beejagranthi Vikar*). **Uttara Vasti** (intrauterine medicated oil administration), performed for two consecutive days per cycle following the cessation of menstrual flow (typically Days 4–10), is highly effective in gynecological disorders.

The mechanism of *Uttara Vasti* (e.g., using 5 ml of *Shatapushpa* oil) validates the *Avarana* theory. The local administration directly purifies and clears the *Aartava Vaha Srotas*, pacifies the vitiated *Apana Vayu* locally, and improves follicular maturity. By resolving the localized obstruction and functional dysregulation, *Uttara Vasti* facilitates successful ovulation, thus providing a targeted intervention against the reproductive consequences of systemic *Sthoulya*.

6.4. Pharmacological Action and Modern Correlates^{ix}

The effectiveness of the Ayurvedic protocol is strongly supported by the pharmacological actions of its constituent herbs, which align with modern interventions for IR and hyperandrogenism.

- Metabolic Correction:** Herbs used for *Medohara* and *Srotoshodhana* actions, such as *Triphala* and *Chandraprabha Vati*, mirror the function of modern insulin sensitizers. Agents like Cinnamon (*Cinnamomum zeylanicum*) and Licorice (*Glycyrrhiza glabra*), frequently studied in PCOS management, improve insulin sensitivity and lower blood glucose and lipid levels.
- Reproductive and Follicular Maturation:** *Shatavari* and *Shatapushpa* regulate the reproductive axis. *Shatavari* supports hormonal balance and *Artava Dhatu* regulation. *Shatapushpa* (carvone, flavonoids) is recognized for its ability to stimulate follicular maturation.
- Androgen Modulation:** While the core regimen focuses on metabolism and ovulation, other recognized Ayurvedic herbs like *Vitex agnus-castus* and Spearmint (*Mentha piperita*) are documented to reduce hyperandrogenism by lowering testosterone and androgen levels, addressing symptoms like hirsutism.

Table 4: Ayurvedic Therapeutic Agents Targeting the Meda-Artava Avarana Complex (with Modern Evidence)^x

Formulation/Herb	Ayurvedic Action (Karma)	Targeted Pathological Step	Clinical Efficacy (Outcome)
<i>Triphala Kwatha</i>	<i>Srotoshodhana</i> , <i>Deepana</i> , <i>Lekhana</i>	Breaking <i>Avarana</i> , Clearing <i>Ama</i> , Improving <i>Jatharagni</i>	Reduction of BMI, normalization of <i>Srotas</i>
<i>Chandraprabha Vati</i>	<i>Medohara</i> , <i>Kapha-Vatahara</i> , <i>Rasayana</i>	Reducing pathological <i>Meda</i> accumulation, restoring <i>Agni</i>	Significant reduction in obesity symptoms
<i>Shatapushpa</i> (<i>P. graveolens</i>)	<i>Artava Janana</i> , <i>Vata Anulomana</i> , Follicular Maturity	Follicular maturation, <i>Artava Kshaya</i> correction	Improvement in follicular maturity, reduction in cysts
<i>Uttara Vasti</i> (Local)	<i>Artavavaha Srotas</i> purification, <i>Apana Vata</i> regulation	Clearing local obstruction, facilitating ovulation and flow	High conception rate (75-85%)

7. Clinical Outcomes and Discussion

7.1. Empirical Validation of the Avarana Theory

The effectiveness of the integrated Ayurvedic approach provides robust empirical validation for the *Meda-Artava Avarana* model. A clinical study utilizing this staged *Shodhana*, *Shamana*, and *Tarpana* regimen over six months reported highly significant therapeutic outcomes in subfertile women with PCOS. The results demonstrated a remarkable **85% cure rate** for the underlying Polycystic Ovarian Syndrome pathology, supported by objective normalization markers. Furthermore, the intervention achieved a **75% conception rate** by the end of the 6-month treatment, which further increased to **85%** after a one-year follow-up, confirming the efficacy in resolving associated *Vandhyatva*. The success of the treatment provides a clear causal link: the systemic management targeting *Sthoulya* and *Avarana* preceded the

resolution of the reproductive *Artava Kshaya*. Objective clinical markers confirmed this causal validation:

- Metabolic Resolution:** Highly significant relief was observed in obesity, with 85% of patients achieving normal BMI levels. This reduction of pathological *Meda* correlates directly with the efficacy of *Srotoshodhana* and *Avarana Vimochana* achieved in Stages 1 and 2.
- Hormonal and Ovarian Correction:** Post-treatment LH/FSH hormone ratios returned to normal levels, and Trans Vaginal Scan (TVS) reports confirmed a substantial reduction in the polycystic appearance of ovaries, alongside improvement in follicular maturity. This demonstrates that removing the *Meda* obstruction allows for the restoration of *Apana Vata* function and the hypothalamic-pituitary-ovarian axis integrity.

8. Conclusion

Polycystic Ovary Syndrome (PCOS) is a complex metabolic and reproductive disorder that can be comprehensively understood through the integrated Ayurvedic concepts of *Sthoulya* (Obesity) and *Artava Kshaya* (Oligo-anovulation). This integrative approach postulates PCOS as a primary **Dhatwagni Mandya Janya Beejagranthi Vikar**, where the core pathology is the *Kapha-Meda Avarana* that physically obstructs the *Artavavaha Srotas* and functionally vitiates *Apana Vata*. Clinical

evidence strongly supports this model: a phased therapeutic regimen utilizing *Shodhana* (channel clearance), *Shamana* (follicular promotion), and *Tarpana* (fortification), significantly reduced obesity (BMI normalization in 85% of patients) and restored reproductive health, yielding a 75-85% conception rate in subfertile women. By systematically targeting the metabolic root (*Sthoulya*) to achieve *Avarana Vimochana*, Ayurveda offers a scientifically viable, root-cause-oriented paradigm for the effective management of the metabolically burdened phenotype of PCOS.

9. References

- ⁱ Luo, Y., Chen, W., Zhang, B., Tang, J., & Li, R. (2024). A novel study about polycystic ovary syndrome: Understanding through the lens of *Artava Kshaya* in traditional Chinese and Indian medicine. *Complementary Therapies in Clinical Practice*, 55, 101839. DOI: 10.1016/j.ctcp.2024.101839.
- ⁱⁱ Acharya, J. T. (Ed.). *Sushruta Samhita: Sharirasthana*, Chapter 2, Shloka 4. Chaukhamba Sanskrit Sansthana. (Reference for *Artava Kshaya Lakshanas: Yathochita Kaala Adarshanam, Alpartavam*).
- ⁱⁱⁱ Azziz, R., Carmina, E., Chen, Z., Dunaif, A., Laven, J. S., Mehran, R. A., & Sisk, R. J. (2014). Androgen excess and PCOS society criteria for the polycystic ovary syndrome: A concordance/discordance analysis. *Human Reproduction*, 29(4), 791–793. DOI: 10.1093/humrep/deu016.
- ^{iv} Shastri, N. (Ed.). *Charaka Samhita: Sutrashtana*, Chapter 21, *Ashtoninditiya Adhyaya*, Shloka 4, 9. (Page No. 414). Chaukhamba Prakashana. (Reference for *Sthoulya Nidana/Samprapti*).
- ^v Acharya, J. T. (Ed.). *Sushruta Samhita: Sharirasthana*, Chapter 3, Shloka 10. (Page No. 345). Chaukhamba Sanskrit Sansthana. (Reference for *Artava Vaha Srotas Mula*).
- ^{vi} The Rotterdam ESHRE/ASRM-Sponsored PCOS Consensus Workshop Group. (2004). Revised 2003 consensus on diagnostic criteria and long-term health risks related to polycystic ovary syndrome (PCOS). *Fertility and Sterility*, 81(1), 19–25. DOI: 10.1016/j.fertnstert.2003.10.004.
- ^{vii} Diamanti-Kandarakis, E., & Dunaif, A. (2007). Insulin resistance and the polycystic ovary syndrome revisited: an update on mechanisms and implications. *Endocrine Reviews*, 28(5), 546–578. DOI: 10.1210/er.2005-0014.
- ^{viii} Dumesic, D. A., Oberfield, S. E., Stener-Victorin, E., Marshall, J. C., & Laven, J. S. (2015). Scientific statement on the diagnostic criteria, epidemiology, pathophysiology, health consequences, and management of polycystic ovary syndrome. *Endocrine Reviews*, 36(2), 270–332. DOI: 10.1210/er.2015-1002.
- ^{ix} Dayani Siriwardene, S. A., Karunathilaka, L. P., Kodituwakku, N. D., & Karunaratne, Y. A. (2011). Clinical evaluation of the efficacy of Ayurveda treatment regimen on subfertility with poly cystic ovarian syndrome (PCOS). *Ayu*, 32(1), 24–27. DOI: 10.4103/0974-8520.85716.
- ^x Wadhwa, A., & Gupta, A. (2022). An Ayurvedic approach of PCOS: Integrating the concept of Dhatwagni Mandya. *International Journal of Research in Health Sciences*, 10(1)..